In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cytovia Inc.

Division of Immune Pharmaceuticals Inc.

Latest From Cytovia Inc.

Deals Shaping the Medical Industry, August 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2017.

Deals BioPharmaceutical

Deal Watch: Gilead And Spring Bank Set Second Trial Collaboration In HBV

Analyst speculates that Gilead could move to acquire Spring Bank if combo trial yields promising data for functional cure of hepatitis B. Eisai in-licenses PARP inhibitor with potential in breast cancer from Oncology Venture, while Sunovion out-licenses three corticosteroid products to Covis.

Deals Commercial

European Biotech: The Flowering of an Industry or Tulip II?

The central message at the Atlas Venture/Ernst & Young European Life Science Conference: the European start-up scene is red hot--hotter than it is in the US. One key reason for a flood of start-ups is the flood of venture funding which has followed the extraordinary performance (until recently) of UK biotech stocks. Another impetus has been Jurgen Ruttgers, Germany's minister of education and research, who has encouraged start-ups through various government spending programs.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Immune Pharmaceuticals Inc.
  • Senior Management
  • Daniel Teper, MD, CEO
  • Contact Info
  • Cytovia Inc.
    Phone: (646) 440-9310
    430 East 29th St.
    Ste. 940
    New York, NY 10016